AAIC 2026 - Our Highlights From Day 2 (July 13): Plasma eMTBR-tau243 as First Disease-Specific Circulating Tau Biomarker; Next-Gen Tau Approaches Progress; CELIA Readout Tomorrow

Research evidence excerpt

AAIC 2026 - Our Highlights From Day 2 (July 13): Plasma eMTBR-tau243 as First Disease-Specific Circulating Tau Biomarker; Next-Gen Tau Approaches Progress; CELIA Readout Tomorrow

Biotechnology July 13, 2026

Yatin Suneja

yatin.suneja@guggenheimpartners.com AAIC 2026 - Our Highlights From Day 2 (July 13):

212 518 9565 Plasma eMTBR-tau243 as First Disease-Specific Delma Caiati, M.D., Ph.D.

delma.caiati@guggenheimpartners.com Circulating Tau Biomarker; Next-Gen Tau Approaches

617 859 4606

Progress; CELIA Readout Tomorrow Eddie Hickman, Ph.D.

eddie.hickman@guggenheimpartners.com

212 518 9904 Key Message: Our highlights from Day 2 (July 13) include: (1) ESAIY presented

Min Lee, Ph.D. Ph1 DIAD data demonstrating that etalanetug (anti-tau mAb) drives tau-tangle-specific

min.lee@guggenheimpartners.com plasma eMTBR-tau243 reductions — 78% at 3 months escalating to >90% at 9 months,

212 823 6744 closely mirroring CSF (62% and 89% at the same timepoints). Undetectable in healthy

Iris Gao, Ph.D. subjects, eMTBR-tau243 functions as a disease-specific pharmacodynamic readout —

iris.gao@guggenheimpartners.com a practical, less-invasive alternative to CSF sampling that should materially improve

212 518 9013 trial execution and patient screening. (2) Discoveric Bio (private) presented a next-

generation anti-tau antibody NIDB-3101 advancing toward FIH Phase 1. NIDB-3101 is

a biparatopic κλ-body simultaneously binding two distinct tau epitopes with engineered

FcRn for extended half-life. Preclinically it delivered impressive anti-seeding activity

(~80% FRET reduction), with NHP PK supporting the company's projected ~110-day

human half-life. (3) VYGR (covered by Debjit Chattopadhyay) presented VY1706, a

BBB-crossing AAV gene therapy delivering up to 75% brain tau lowering through 6